Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group

scientific article published in August 1996

Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1056/NEJM199608083350604
P698PubMed publication ID8676932

P50authorA Clinton WhiteQ44838503
Donald N ForthalQ89741676
P2093author name stringMcCutchan JA
Kemper CA
Bozzette SA
Parenti DM
Dubé MP
Havlir DV
Sattler FR
Lavelle JP
Dunne MW
Witt MD
P433issue6
P407language of work or nameEnglishQ1860
P921main subjectCaliforniaQ99
rifabutinQ1135705
collaborationQ1145523
azithromycinQ165399
Mycobacterium avium aviumQ310728
P304page(s)392-398
P577publication date1996-08-01
P1433published inThe New England Journal of MedicineQ582728
P1476titleProphylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group
P478volume335

Reverse relations

cites work (P2860)
Q736054371999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA)
Q356146312001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus
Q446165682001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus
Q74683288AIDS-related Mycobacterium kansasii infection with initial resistance to clarithromycin
Q28344776Activity of ABT-773 against Mycobacterium avium complex in the beige mouse model
Q35733945Antibiotic trials for coronary heart disease
Q33659379Antiinfectives update: focus on treatment and prevention of viral and associated infections
Q34115343Assessing the performance of a computer-based policy model of HIV and AIDS
Q33978221Azithromycin as treatment for disseminated Mycobacterium avium complex in AIDS patients
Q35302808Azithromycin for ocular toxoplasmosis
Q46496257Azithromycin pulses in the treatment of inflammatory and pustular acne: efficacy, tolerability and safety
Q36281588Bacterial infections in adult HIV-infected patients
Q43801101Characteristics and mechanisms of azithromycin accumulation and efflux in human polymorphonuclear leukocytes
Q37883369Choosing the right macrolide antibiotic. A guide to selection
Q33980683Clarithromycin-resistant mycobacterium avium is still susceptible to treatment with clarithromycin and is virulent in mice
Q73456232Comparison of azithromycin leukocyte disposition in healthy volunteers and volunteers with AIDS
Q33584119Cost effectiveness of prophylaxis for opportunistic infections in AIDS. An overview and methodological discussion.
Q50141101Cost-effectiveness of azithromycin for preventing Mycobacterium avium complex infection in HIV-positive patients in the era of highly active antiretroviral therapy. The Swiss HIV Cohort Study
Q28265322Current treatment of atypical mycobacteriosis
Q22241907Diagnosis and Treatment of Disease Caused by Nontuberculous Mycobacteria
Q41730934Discontinuing prophylaxis for opportunistic infection: guiding principles
Q43787824Disseminated Mycobacterium avium complex disease among patients infected with human immunodeficiency virus, 1985-2000.
Q35693261Disseminated mycobacterium avium-intracellulare complex (MAC) infection in the era of effective antiretroviral therapy: is prophylaxis still indicated?
Q34727977Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by Mycobacterium avium complex prophylaxis in HIV
Q41331963Drug treatment of HIV-related opportunistic infections
Q90497585Effect of Macrolide Prophylactic Therapy on AIDS-Defining Conditions and HIV-Associated Mortality
Q41690799Efficacy of azithromycin in prevention of Pneumocystis carinii pneumonia: a randomised trial. California Collaborative Treatment Group
Q28379322Emergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy.
Q54139769Evaluation of a disk diffusion method for determining susceptibility of Mycobacterium avium complex to clarithromycin.
Q34393599Expanded HIV screening in the United States: what will it cost government discretionary and entitlement programs? A budget impact analysis.
Q40657726Fever of unknown origin in the HIV-infected patient: new scenario for an old problem
Q91984625Global access of rifabutin for the treatment of tuberculosis - why should we prioritize this?
Q35818518Global strategies to prevent bacterial pneumonia in adults with HIV disease
Q74404199Granulocyte colony-stimulating factor use is associated with decreased bacteremia and increased survival in neutropenic HIV-infected patients
Q93501240HIV: prevention of opportunistic infections
Q33850498HIV: primary and secondary prophylaxis for opportunistic infections
Q45751850Human immunodeficiency virus infection, Part II.
Q39100345Immunomodulatory indications of azithromycin in respiratory disease: a concise review for the clinician
Q43599627Impact of prophylaxis for Mycobacterium avium complex on bacterial infections in patients with advanced human immunodeficiency virus disease.
Q37415433Improving outcomes in state AIDS drug assistance programs
Q35558806Infections in Patients with Inherited Defects in Phagocytic Function
Q41678925Innovative approaches to novel antibacterial drug discovery
Q42762413Interferon-γ Autoantibodies as Predisposing Factor for Nontuberculous Mycobacterial Infection
Q24197892Interventions for the prevention of mycobacterium avium complex in adults and children with HIV
Q36311794Is primary mycobacterium avium complex prophylaxis necessary in patients with CD4 <50 cells/μL who are virologically suppressed on cART?
Q30779044Joint modeling of survival and longitudinal non-survival data: current methods and issues. Report of the DIA Bayesian joint modeling working group
Q32039126Lack of an effect of azithromycin on the disposition of zidovudine and dideoxyinosine in HIV-infected patients
Q39226202Long term treatment with clarithromycin for cryptosporidiosis and emergence of drug resistant disseminated infection due to Mycobacterium avium: case report
Q36170393Macrolides: A Canadian Infectious Disease Society position paper
Q24679338Management of opportunist mycobacterial infections: Joint Tuberculosis Committee Guidelines 1999. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society
Q28343464Mefloquine is active in vitro and in vivo against Mycobacterium avium complex
Q45081834Model for simulation of HIV/AIDS and cost-effectiveness of preventing non-tuberculous mycobacterial (MAC)-disease
Q33977716Mononuclear and polymorphonuclear leukocyte dispositions of clarithromycin and azithromycin in AIDS patients requiring Mycobacterium avium complex prophylaxis.
Q54120812Mycobacteria as pathogens of respiratory infection.
Q41336741Mycobacterial complications of HIV infection
Q35874064Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy
Q37202852Mycobacterium avium complex infection in HIV/AIDS patients
Q34569262Nontuberculous mycobacteria immune reconstitution syndrome
Q34949978Nontuberculous mycobacteria in the HIV infected patient
Q35779935Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients
Q30426863Nontuberculous mycobacterial infections
Q42272342Nontuberculous mycobacterial infections in solid organ transplantation
Q33851989Opportunistic infections and other clinical manifestations of HIV disease in children
Q34305079Opportunistic infections in HIV disease: down but not out.
Q37848432Oral azithromycin in extended dosage schedule for chronic, subclinical Chlamydia pneumoniae infection causing coronary artery disease: a probable cure in sight? Results of a controlled preliminary trial
Q44766862Outpatient management of HIV-infected adults. The varied challenges for primary care
Q41710621Overview of protease inhibitors.
Q35692736Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections
Q41615483Preventing and treating major opportunistic infections in AIDS. What's new and what's still true
Q45752626Prevention and treatment of disseminated Mycobacterium avium complex infection in human immunodeficiency virus-infected individuals
Q44255331Prevention of human immunodeficiency virus-related opportunistic infections in France: a cost-effectiveness analysis.
Q35677256Prevention of opportunistic infections in adult and adolescent patients with HIV infection. GESIDA/National AIDS Plan guidelines, 2004 [correction].
Q41633522Prevention strategies for Mycobacterium avium-intracellulare complex (MAC) infection. A review of recent studies in patients with AIDS.
Q35007043Projected survival gains from revising state laws requiring written opt-in consent for HIV testing.
Q33544612Prophylaxis against disseminated Mycobacterium avium complex in AIDS.
Q34122368Prophylaxis of opportunistic infections.
Q33936966Randomised trials of STD treatment for HIV prevention: report of an international workshop. HIV/STD Trials Workshop Group
Q37876312Rationale and design of a secondary prevention trial of antibiotic use in patients after myocardial infarction: the WIZARD (weekly intervention with zithromax [azithromycin] for atherosclerosis and its related disorders) trial
Q41633512Rationale for the prevention of disseminated Mycobacterium avium-intracellulare complex disease.
Q47829087Recurrent Mycobacterium xenopi infection in a patient with rheumatoid arthritis receiving etanercept.
Q38786540Rifabutin: where do we stand in 2016?
Q50883380Risk factors for rifampin mono-resistant tuberculosis.
Q33717062Risk-benefit assessment of therapies for Mycobacterium avium complex infections
Q33970989Serum interleukin-6 (IL-6), IL-10, tumor necrosis factor (TNF) alpha, soluble type II TNF receptor, and transforming growth factor beta levels in human immunodeficiency virus type 1-infected individuals with Mycobacterium avium complex disease
Q71849403Severe neutropenia and prophylactic doses of rifabutin
Q45001768Small Intestinal Infections
Q41521259The Role of Advanced Generation Macrolides in the Prophylaxis and Treatment of Mycobacterium avium Complex (MAC) Infections
Q53927453The effect of azithromycin on the pharmacokinetics of indinavir.
Q34777454The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach
Q41527229The therapy of gastrointestinal infections associated with the acquired immunodeficiency syndrome
Q44727844Therapeutic innovations for environmental mycobacteria
Q37180338Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066)
Q30951402Tolerability of azithromycin as malaria prophylaxis in adults in northeast papua, indonesia
Q33982133Tolerance and pharmacokinetic interactions of rifabutin and azithromycin
Q33691292Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.
Q74599772Treatment and prophylaxis of disseminated Mycobacterium avium complex in HIV-infected individuals
Q41648609Treatment of nontuberculous mycobacterial infections: role of clarithromycin and azithromycin
Q41614452Tuberculosis and HIV infection: a review
Q37865389Update of antibiotic trials for secondary prevention of coronary heart disease
Q74775416[Disseminated infection with Mycobacterium avium complex (MAC) in HIV infection]
Q77396620[HIV protease inhibitors: drug interactions]
Q81643225[Respiratory infections caused by environmental mycobacteria]

Search more.